Skip to main content
Clinical Trials/KCT0008733
KCT0008733
Not yet recruiting
未知

A single-arm phase II trial of Atezolizumab and Bevacizumab with combined radiotherapy in advanced hepatocellular carcinoma with portal vein invasion

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Yonsei University Health System, Severance Hospital
Enrollment
51
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) age \=19
  • (2\) clinically or histologically diagnosed HCC
  • (3\) HCC with Vp2\-Vp4 portal vein invasion
  • (4\) intact liver function with Child\-Pugh class A
  • (5\) adequate size of RT field
  • (6\) adequate liver function
  • ; AST/ALT \=5 times the upper limits of normal)
  • ; no coagulopathy
  • (7\) intact performance with ECOG below 2
  • (8\) non\-pregnant with acceptable contraception in premenopausal women)

Exclusion Criteria

  • (1\) Active uncontrolled infection; (2\) Current or history (\< or \= 5 years) of advanced malignancies in the other organs; (3\) History of liver transplantation; (4\) miliary HCC which incompatible external beam RT

Outcomes

Primary Outcomes

Not specified

Similar Trials